Scott R Auerbach1, Jane Gralla, David N Campbell, Shelley D Miyamoto, Biagio A Pietra. 1. 1 Pediatrics, Division of Pediatric Cardiology, School of Medicine, University of Colorado Aurora, CO. 2 Pediatrics, Children's Hospital Research Institute, School of Medicine, University of Colorado Aurora, CO. 3 Pediatric Cardiac Surgery, School of Medicine, University of Colorado Aurora, CO. 4 Address correspondence to: Scott R. Auerbach, M.D., School of Medicine, University of Colorado Denver, Children's Hospital Colorado Heart Institute, 13123 E 16th Ave, B100 Aurora, CO 80238.
Abstract
BACKGROUND: Maintenance steroid (MS) use in pediatric heart transplantation (HT) varies across centers. The purpose of this study was to evaluate the impact of steroid-free maintenance immunosuppression (SF) on graft outcomes in pediatric HT. METHODS: Patients younger than 18 years in the United States undergoing a first HT during 1990 to 2010 were analyzed for conditional 30-day graft loss (death or repeat HT) and death based on MS use by multivariable analysis. A propensity score was then given to each patient using a logistic model, and propensity matching was performed using pre-HT risk factors, induction therapy, and nonsteroid maintenance immunosuppression. Kaplan-Meier graft and patient survival probabilities by MS use were then calculated. RESULTS: Of 4894 patients, 3962 (81%) were taking MS and 932 (19%) SF. Of the 4530 alive at 30 days after HT, 3694 (82%) and 836 (18%) were in the MS and SF groups, respectively. Unmatched multivariable analysis showed no difference in 30-day conditional graft survival between MS and SF groups (hazard ratio=1.08, 95% confidence interval=0.93-1.24; P=0.33). Propensity matching resulted in 462 patients in each MS and SF group. Propensity-matched Kaplan-Meier survival analysis showed no difference in graft or patient survival between groups (P=0.3 and P=0.16, respectively). CONCLUSIONS: We found no difference in graft survival between SF patients and those taking MS. An SF regimen in pediatric HT avoids potential complications of steroid use without compromising graft survival, even after accounting for pre-HT risk factors.
BACKGROUND: Maintenance steroid (MS) use in pediatric heart transplantation (HT) varies across centers. The purpose of this study was to evaluate the impact of steroid-free maintenance immunosuppression (SF) on graft outcomes in pediatric HT. METHODS:Patients younger than 18 years in the United States undergoing a first HT during 1990 to 2010 were analyzed for conditional 30-day graft loss (death or repeat HT) and death based on MS use by multivariable analysis. A propensity score was then given to each patient using a logistic model, and propensity matching was performed using pre-HT risk factors, induction therapy, and nonsteroid maintenance immunosuppression. Kaplan-Meier graft and patient survival probabilities by MS use were then calculated. RESULTS: Of 4894 patients, 3962 (81%) were taking MS and 932 (19%) SF. Of the 4530 alive at 30 days after HT, 3694 (82%) and 836 (18%) were in the MS and SF groups, respectively. Unmatched multivariable analysis showed no difference in 30-day conditional graft survival between MS and SF groups (hazard ratio=1.08, 95% confidence interval=0.93-1.24; P=0.33). Propensity matching resulted in 462 patients in each MS and SF group. Propensity-matched Kaplan-Meier survival analysis showed no difference in graft or patient survival between groups (P=0.3 and P=0.16, respectively). CONCLUSIONS: We found no difference in graft survival between SFpatients and those taking MS. An SF regimen in pediatric HT avoids potential complications of steroid use without compromising graft survival, even after accounting for pre-HT risk factors.
Authors: Mark J Russo; Jonathan M Chen; Robert A Sorabella; Timothy P Martens; Mauricio Garrido; Ryan R Davies; Isaac George; Faisal H Cheema; Ralph S Mosca; Seema Mital; Deborah D Ascheim; Michael Argenziano; Allan S Stewart; Mehmet C Oz; Yoshifumi Naka Journal: J Thorac Cardiovasc Surg Date: 2007-02 Impact factor: 5.209
Authors: T P Singh; D C Naftel; L Addonizio; W Mahle; M T Foushee; S Zangwill; E D Blume; J K Kirklin; R Singh; J K Johnston; R Chinnock Journal: Am J Transplant Date: 2010-09 Impact factor: 8.086
Authors: Scott R Auerbach; Jilayne K Smith; Jane Gralla; Max B Mitchell; David N Campbell; Jim Jaggers; Biagio A Pietra; Shelley D Miyamoto Journal: J Heart Lung Transplant Date: 2012-07-11 Impact factor: 10.247
Authors: Scott R Auerbach; Marc E Richmond; Jonathan M Chen; Ralph S Mosca; Jan M Quaegebeur; Linda J Addonizio; Daphne T Hsu; Jacqueline M Lamour Journal: Pediatr Cardiol Date: 2011-09-04 Impact factor: 1.655
Authors: D A Fullerton; D N Campbell; S D Jones; J Jaggers; J M Brown; M M Wollmering; F L Grover; C Mashburn; M Luna; H M Sondheimer Journal: Ann Thorac Surg Date: 1995-04 Impact factor: 4.330
Authors: Beatrice Dionigi; Anees J Razzouk; Nahidh W Hasaniya; Richard E Chinnock; Leonard L Bailey Journal: J Heart Lung Transplant Date: 2008-10 Impact factor: 10.247
Authors: Tajinder P Singh; Carey Faber; Elizabeth D Blume; Sarah Worley; Christopher S Almond; Leslie B Smoot; Shay Dillis; Colleen Nasman; Gerard J Boyle Journal: J Heart Lung Transplant Date: 2010-01-12 Impact factor: 10.247
Authors: Martin Schweiger; Andreas Zuckermann; Andres Beiras-Fernandez; Michael Berchtolld-Herz; Udo Boeken; Jens Garbade; Stephan Hirt; Manfred Richter; Arjang Ruhpawar; Jan Dieter Schmitto; Felix Schönrath; Rene Schramm; Uwe Schulz; Markus J Wilhelm; Markus J Barten Journal: Ann Transplant Date: 2018-05-15 Impact factor: 1.530